Skip to main content
. 2023 Sep 3;8(12):2529–2545. doi: 10.1016/j.ekir.2023.08.037

Figure 1.

Figure 1

Relative contributions of immunosuppression drugs in the current Emory University belatacept protocol. The protocol consists of basiliximab induction and an early low-dose bridge of tacrolimus to minimize early rejections that is weaned off starting at 9 months post-transplant, leaving patients on calcineurin inhibitor-free prednisone, MMF and monthly belatacept maintenance therapy long-term. MMF, mycophenolate mofetil.